The phenomenal growth of the Small Interfering RNA Market—projected to reach a total market size of USD 521.7 Billion by 2035 at an 11.02% CAGR—is intrinsically linked to the successful evolution of delivery technology. While early siRNA therapies primarily targeted the liver, the true market future and maximal opportunity depend on effectively delivering these molecules to...

Small interfering RNA therapeutics — the double-stranded RNA molecules of approximately twenty-one to twenty-three nucleotides that trigger RNA interference silencing specific disease-causing genes through the RISC (RNA-induced silencing complex) pathway — represent one of the most transformative pharmaceutical modalities in modern medicine, with the Small Interfering RNA Market...